소라페닙 치료 간세포암 환자에서 발생한 드레스 증후군 1예

Sorafenib is currently the only targeted therapy available for advanced stage hepatocellular carcinoma (HCC). Cutaneous adverse events associated with sorafenib treatment include hand-foot skin reaction, but there has been no report of drug reaction (or rash) with eosinophilia and systemic symptoms...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of gastroenterology Vol. 67; no. 6; pp. 337 - 340
Main Authors 김동균, Dong Kyun Kim, 이성우, Sung Woo Lee, 남화성, Hwa Seong Nam, 전동섭, Dong Sub Jeon, 박나래, Na Rae Park, 남영희, Young Hee Nam, 이수걸, Soo Keol Lee, 백양현, Yang Hyun Baek, 한상영, Sang Young Han, 이성욱, Sung Wook Lee
Format Journal Article
LanguageKorean
Published 대한소화기학회 30.06.2016
Subjects
DRESS syndrome
Hepatocellular carcinoma
Sorafenib
Online AccessGet full text

Cover

More Information
Summary:Sorafenib is currently the only targeted therapy available for advanced stage hepatocellular carcinoma (HCC). Cutaneous adverse events associated with sorafenib treatment include hand-foot skin reaction, but there has been no report of drug reaction (or rash) with eosinophilia and systemic symptoms (DRESS) syndrome. Here, we report a case of 72-year-old man with HCC and alcoholic liver cirrhosis who developed skin eruptions, fever, eosinophilia, and deteriorated hepatic and renal function under sorafenib treatment. He has since successfully recovered with conservative care. (Korean J Gastroenterol 2016;67:337-340)
Bibliography:Korean Society of Gastroenterology
ISSN:1598-9992